Video

Barriers to Optimal Prescribing of SGLT2 Inhibitors and GLP-1 Receptor Agonists

Muthiah Vaduganathan, MD, MPH, of Brigham and Women's discusses the barriers to preventing optimal prescribing practices for SGLT2 inhibitor and GLP-1 receptor agonist therapies.

Backed by data from a multitude of clinical trials released in recent years, SGLT2 inhibitors and GLP-1 receptor agonists have been the subject of discussion for specialists across multiple fields. In a recent scientific statement, the American Heart Association (AHA) outlined the apparent cardiorenal protection seen with the agents in major studies and also provided insight into determining which agent may be most appropriate for differing patient populations.

In the following interview, you will hear from Muthiah Vaduganathan, MD, MPH, a member of the writing committee for the aforementioned statement and a cardiologist at Brigham and Women’s Hospital. In the interview, Vaduganathan offers his perspective on why these classes of antidiabetes medications are under-prescribed despite the clearly defined benefit seen with either or both classes.




Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Orly Vardeny, PharmD: Finerenone for Heart Failure with EF >40% in FINEARTS-HF | Image Credit: JACC Journals
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
© 2024 MJH Life Sciences

All rights reserved.